A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Selumetinib (Primary)
- Indications Glioma; Neurofibromatoses
- Focus Adverse reactions; Therapeutic Use
- Acronyms INSPECT
- 26 Feb 2018 Planned initiation date changed from 1 Oct 2017 to 1 Mar 2018.
- 02 Nov 2017 New trial record
- 01 Nov 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019.